Paradigm Biocapital Advisors LP Cullinan Oncology, Inc. Transaction History
Paradigm Biocapital Advisors LP
- $2.47 Billion
- Q2 2024
A detailed history of Paradigm Biocapital Advisors LP transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Paradigm Biocapital Advisors LP holds 1,542,805 shares of CGEM stock, worth $26.5 Million. This represents 1.09% of its overall portfolio holdings.
Number of Shares
1,542,805
Previous 1,348,015
14.45%
Holding current value
$26.5 Million
Previous $23 Million
17.14%
% of portfolio
1.09%
Previous 0.86%
Shares
2 transactions
Others Institutions Holding CGEM
# of Institutions
140Shares Held
65.9MCall Options Held
77.2KPut Options Held
15.9K-
Bio Impact Capital LLC Cambridge, MA7.65MShares$131 Million21.42% of portfolio
-
Bvf Inc San Francisco, CA5.75MShares$98.9 Million3.07% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$61 Million0.0% of portfolio
-
Chi Advisors LLC New York, NY3.41MShares$58.7 Million15.23% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.28MShares$56.4 Million1.2% of portfolio
About Cullinan Oncology, Inc.
- Ticker CGEM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,612,200
- Market Cap $784M
- Description
- Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...